Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Claritin/Singulair; Montelukast/loratadine

Latest Information Update: 22 Mar 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Schering-Plough/Merck Pharmaceuticals
  • Class Acetates; Antiallergics; Antiasthmatics; Dibenzocycloheptenes; Nonsedating antihistamines; Piperidines; Quinolines
  • Mechanism of Action Histamine H1 receptor antagonists; Leukotriene D4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Seasonal allergic rhinitis

Most Recent Events

  • 27 Jun 2008 Schering-Plough/Merck Pharmaceuticals withdraws NDA for loratadine/montelukast in Seasonal allergic rhinitis
  • 25 Apr 2008 Schering-Plough/Merck Pharmaceuticals receives non-approvable letter from the FDA for loratadine/montelukast in Seasonal allergic rhinitis
  • 30 Aug 2007 Preregistration for Seasonal allergic rhinitis in USA (PO), FDA has accepted filing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top